Author:
Zambrano Ibardo A.,Demzik Alysen,Bjurlin Marc A.
Publisher
Springer International Publishing
Reference120 articles.
1. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103(2):117–28. https://doi.org/10.1093/jnci/djq495.
2. Stav K, Leibovici D, Goren E, Livshitz A, Siegel YI, Lindner A, et al. Adverse effects of cystoscopy and its impact on patients’ quality of life and sexual performance. Isr Med Assoc J. 2004;6(8):474–8.
3. Herr HW. The risk of urinary tract infection after flexible cystoscopy in patients with bladder tumor who did not receive prophylactic antibiotics. J Urol. 2015;193(2):548–51. https://doi.org/10.1016/j.juro.2014.07.015.
4. Lotan Y, Bivalacqua TJ, Downs T, Huang W, Jones J, Kamat AM, et al. Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018. Nat Rev Urol. 2019;16(6):377–86. https://doi.org/10.1038/s41585-019-0184-4.
5. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196(4):1021–9. https://doi.org/10.1016/j.juro.2016.06.049.